Drug companies assure NPPA of uninterrupted supplies of stents

After NPPA reduced the price of stents, there was a sudden shortage of stents in the market reportedly artificially created by manufacturers

stent illustration

Drug companies have assured Secretary Pharma & Chairman National Pharmaceuticals Pricing Authority (NPPA) of India that they will ensure uninterrupted supplies and will not withdraw any brand. The NPPA on Monday announced cut prices of life—saving coronary stents by up to 85 per cent by capping them at Rs 7,260 for bare metal ones and Rs 29,600 for drug eluting variety.

Following the order, cardiac stents especially the high end ones, were taken away from the cath-labs in the name of relabeling and cardiologists have been facing a shortage in some of the stents.

To ensure, the cath-labs are having adequate supply of stents, the Food and Drugs Administration (FDA), Maharashtra carried out survey in some of the hospitals in Mumbai region.

NPPA too has been issuing notices asking the manufacturers to ensure there is adequate supply of stents in the market. It said withdrawal of stents from hospitals for changing MRP or relabeling not required.

In case of shortage or unavailability all concerned may contact Food & Drug Administration, Maharashtra State on help line no. 1800222365, Vinita Thomas, Joint commissioner Greater Mumbai. 26592363-65 /  26590686, V.T. Paunikar Joint Commissioner . KD. –022  – 25811988/25821245

NPPA’s new helpline number: 1800111255

Available 24×7 to register complaints regarding prices and supply & availability of coronary stents